• LAST PRICE
    7.0500
  • TODAY'S CHANGE (%)
    Trending Down-0.4200 (-5.6225%)
  • Bid / Lots
    7.0400/ 5
  • Ask / Lots
    7.0600/ 5
  • Open / Previous Close
    7.4500 / 7.4700
  • Day Range
    Low 7.0000
    High 7.5200
  • 52 Week Range
    Low 2.1800
    High 13.6800
  • Volume
    187,729
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 7.47
TimeVolumeLRMR
09:32 ET33457.51
09:34 ET9067.45
09:36 ET2007.41
09:39 ET1007.42
09:41 ET3987.45
09:48 ET1007.41
09:52 ET4007.35
09:57 ET17937.305
09:59 ET14147.3
10:01 ET7307.28
10:03 ET1007.26
10:06 ET36007.28
10:08 ET14187.24
10:10 ET7507.21
10:12 ET3007.195
10:17 ET1007.215
10:19 ET10057.21
10:21 ET25007.29
10:24 ET3007.31
10:26 ET29767.295
10:32 ET7717.2833
10:35 ET12647.33
10:37 ET9007.355
10:39 ET1007.34
10:42 ET14387.33
10:44 ET5507.2998
10:46 ET1007.29
10:48 ET2007.29
10:53 ET4007.3
10:55 ET3157.3
10:57 ET5287.31
11:00 ET6007.28
11:02 ET2007.285
11:04 ET5007.2821
11:08 ET43447.265
11:11 ET10007.29
11:13 ET8007.28
11:15 ET36597.21
11:18 ET5007.225
11:22 ET9637.2
11:24 ET3007.21
11:26 ET5007.23
11:27 ET3507.24
11:29 ET1007.24
11:36 ET7307.23
11:38 ET6377.2
11:40 ET5007.18
11:42 ET1007.155
11:44 ET1007.15
11:45 ET23007.14
11:47 ET41157.155
11:49 ET4007.155
11:51 ET5977.15
11:54 ET10207.12
11:56 ET4007.12
12:02 ET16507.13
12:03 ET11007.17
12:05 ET1007.1952
12:07 ET3007.195
12:12 ET2007.2091
12:16 ET17407.245
12:20 ET3007.2599
12:25 ET56087.21
12:27 ET9087.21
12:34 ET8847.19
12:36 ET14007.21
12:38 ET43787.19
12:39 ET11257.1835
12:41 ET27467.19
12:43 ET3007.18
12:45 ET3997.17
12:48 ET1007.185
12:50 ET37247.16
12:56 ET1007.165
12:57 ET2007.15
12:59 ET15507.14
01:01 ET20127.1391
01:03 ET4007.12
01:08 ET5007.125
01:17 ET18027.091
01:19 ET6227.07
01:21 ET2007.085
01:24 ET2037.085
01:26 ET3007.073
01:28 ET16207.1
01:30 ET1007.1
01:33 ET8717.08
01:35 ET1607.08
01:37 ET4007.07
01:39 ET11487.06
01:42 ET5027.06
01:46 ET1007.07
01:50 ET1007.07
01:51 ET2037.08
01:53 ET1007.07
01:55 ET3287.0684
01:57 ET4007.06
02:00 ET3007.06
02:02 ET4007.05
02:08 ET2377.035
02:09 ET2507.025
02:11 ET2007.025
02:13 ET1007.025
02:15 ET13007.03
02:18 ET2507.02
02:20 ET1007.03
02:22 ET1007.03
02:26 ET73287.03
02:27 ET7007.02
02:29 ET14007.028
02:33 ET21007.03
02:38 ET6507.02
02:44 ET4007.02
02:47 ET1007.02
02:49 ET4007.02
02:51 ET4047.02
02:54 ET15277.03
02:56 ET4027.03
02:58 ET10007.0399
03:00 ET32017.045
03:02 ET56137.0516
03:03 ET23767.042
03:05 ET58947.03
03:14 ET10007.03
03:16 ET16007.03
03:18 ET30117.06
03:21 ET14447.06
03:23 ET7757.07
03:25 ET3007.07
03:27 ET3007.07
03:30 ET6007.07
03:32 ET2567.05
03:34 ET8007.05
03:36 ET8007.05
03:38 ET2007.05
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesLRMR
Larimar Therapeutics Inc
476.6M
-7.3x
---
United StatesKALV
Kalvista Pharmaceuticals Inc
476.3M
-3.6x
---
United StatesOLMA
Olema Pharmaceuticals Inc
488.3M
-4.4x
---
United StatesPEPG
PepGen Inc
461.6M
-4.5x
---
United StatesNKTX
Nkarta Inc
460.9M
-2.7x
---
United StatesAVTE
Aerovate Therapeutics Inc
493.5M
-5.7x
---
As of 2024-05-24

Company Information

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. It intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Contact Information

Headquarters
THREE BALA PLAZA EAST. SUITE 506BALA CYNWYD, PA, United States 19004
Phone
617-622-4003
Fax
302-655-5049

Executives

Independent Chairman of the Board
Joseph Truitt
President, Chief Executive Officer, Director
Carole Ben-Maimon
Chief Financial Officer, Company Secretary
Michael Celano
Chief Medical Officer
Russell Clayton
Chief Development Officer
Gopi Shankar

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$476.6M
Revenue (TTM)
$0.00
Shares Outstanding
63.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.86
EPS
$-0.97
Book Value
$1.86
P/E Ratio
-7.3x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.